You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index in December.
The investment bank said that while Twist's biopharma and DNA-based data storage businesses offer upside, the timelines for generating revenues are unclear.
Although the total number of deals went down in 2020, those deals were worth more compared to 2019 — four of the top five had billion-dollar price tags.
A recently published preprint study demonstrated the superiority of the company's optical mapping technology for detecting large structural variations in de novo sequencing data.
Originally, the company had said it was planning to offer $250 million worth of shares in the offering, which is expected to close Dec. 7.
Included in the offering — Twist Bioscience's third this year — are 75,000 shares of common stock offered by certain selling shareholders.
The index underperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, which all swung up on positive coronavirus vaccine news.
The GenomeWeb Index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, which all fell in October.
The investment bank projects medium-term revenue growth in the low teens, thanks to new test launches and expanded payor contracts for the company.
The synbio company offers scale and lower costs in "massive" end markets, SVB Leerink analysts said, and could soon command an even more attractive valuation.
NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.
According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.
In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.
Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.